Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Assets Average: 2021-2025

Historic Assets Average for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Assets Average rose 25.19% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 25.19%. This contributed to the annual value of $937.1 million for FY2024, which is 36.13% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Assets Average is $1.2 billion, which was up 7.49% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Assets Average ranged from a high of $1.2 billion in Q3 2025 and a low of $443.3 million during Q2 2021.
  • Moreover, its 3-year median value for Assets Average was $885.5 million (2024), whereas its average is $886.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Assets Average fell by 12.30% in 2023, and later soared by 53.32% in 2024.
  • Quarterly analysis of 5 years shows Krystal Biotech's Assets Average stood at $538.7 million in 2021, then increased by 5.33% to $567.4 million in 2022, then soared by 41.76% to $804.4 million in 2023, then increased by 26.70% to $1.0 billion in 2024, then grew by 25.19% to $1.2 billion in 2025.
  • Its Assets Average stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.